Brief: Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
03/12/2024 12:43
Dec 3 (Reuters) - Adaptive Biotechnologies Corp
ADPT.O :
* ADAPTIVE BIOTECHNOLOGIES ANNOUNCES OVER 65 ABSTRACTS
FEATURING
CLONOSEQ® MRD TESTING ACROSS A RANGE OF BLOOD CANCERS TO BE
PRESENTED AT THE 66TH ASH ANNUAL MEETING
Source text: ID:nGNX580762
Further company coverage: ADPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adaptive Biotechnologies
See all newsAdvisory: Alert incorrectly tagged to Adaptive Biotechnologies withdrawn
U.S. RESEARCH ROUNDUP-Cloudflare, Replimune, Walmart
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Adaptive Biotechnologies Corp reports results for the quarter ended June 30 - Earnings Summary
Adaptive Biotechnologies Q2 revenue rises 22%, beats estimates